Core Insights - The company's Q4 performance is attributed to successful expansion of the US sales force and initial revenue contributions from early launches in Germany, France, and Japan [1] - The US market is shifting towards a 'start-stop' treatment regime for longer-tenured patients as disease management stabilizes [1] - International expansion is identified as the primary revenue growth driver for 2026, leveraging a larger patient pool outside the US and favorable product labels [1] - The company is maintaining a disciplined capital allocation strategy, aiming to compound value through operating profitability without relying on equity dilution [1] - High gross margins of 94% were achieved through efficient manufacturing, though slightly offset by higher unit costs for initial international volumes ahead of planned optimizations [1] - Strategic positioning focuses on self-launching four potential upcoming indications and building a specialized commercial infrastructure for rare genetic medicines [1]